课题基金 / 基金详情

SR141716, Rimonabant, to reduce alcohol consumption

SR141716, Rimonabant, to reduce alcohol consumption
SR141716，利莫那班，减少酒精消耗
批准号：
7146650
负责人：
David T George
金额：
$0.0万
依托单位：
NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/7146650
关键词：
alcoholic beverage consumptionalcoholism /alcohol abusealcoholism /alcohol abuse chemotherapyalcoholism antagonistbreath testscannabinoid receptorclinical trialshuman subjecthuman therapy evaluationinhibitor /antagonistpatient oriented research

项目摘要

项目成果

David T George的其他基金

相关文献

中文摘要
翻译
利莫那班是一种CB1大麻素受体拮抗剂，已经在动物身上证明可以减少酒精消耗。该方案旨在确定利莫那班是否会减少每周饮酒20至50杯的人的饮酒量。迄今为止，已有20名参与者参加了这项双盲研究。在研究完成之前，不会进行数据分析。
英文摘要
Rimonabant is a CB1 cannabinoid receptor antagonist which has been shown in animals to reduce alcohol consumption. This protocol is intended to determine if Rimonabant will decrease alcohol consumption in individuals who consume between 20 and 50 drinks of alcohol per week. To date, twenty participants have been enrolled in this double-blind study. Data analysis will not be preformed until the study is complete.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Assessment,Treatment, and Pharmacological Interventions in Alcoholic Patients
Characterization Of Perpetrators Of Domestic Violence
Clinical trial of SR141716, Rimonabant, to reduce volunt
Characterization Of Perpetrators Of Domestic Violence